Score Overview
PeriodNet IncomeRevenueScoreGrowthTrendConsistencyGrowthTrendConsistency
5 Years
3.1
-215.10%
20%
—
8x
60%
—
5 Years
Score3.1
Net Growth-215.10%
Net Trend20%
Net Income Consistency—
Rev Growth8x
Rev Trend60%
Revenue Consistency—
Janux Therapeutics Inc fundamental performance
Between 2021 and 2025, revenue grew from $ 3M to $ 10M and net income went from -$ 32M to -$ 113M. Revenue increased in 60% of the years measured; net income in 20%.
Janux Therapeutics Inc currently holds a 5-year HDB Score of 3.1 out of 10. How the HDB Score is calculated.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-08-12 | $ 16.67 | — |
1 Year2025-08-12 | $ 24.27 | -31.31% |
5 Years2021-08-12 | $ 32.22 | -48.26% |
All Time2021-06-11 | $ 25.15 | -33.72% |
| Period | Last Price2026-08-12 | 1 Year2025-08-12 | 5 Years2021-08-12 | All Time2021-06-11 |
|---|---|---|---|---|
| Price | $ 16.67 | $ 24.27 | $ 32.22 | $ 25.15 |
| Return | — | -31.31% | -48.26% | -33.72% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | $ 31M | -$ 102M | $ 970M |
| 2025 | $ 10M | -$ 113M | $ 966M |
| 2024 | $ 10M | -$ 68M | $ 1.02B |
| 2023 | $ 8M | -$ 58M | $ 344M |
| 2022 | $ 8M | -$ 54M | $ 327M |
| IPO2021 | $ 3M | -$ 32M | $ 374M |
Explore beyond JANX
You're looking at Janux Therapeutics Inc. Members apply the same fundamental framework across all 3,860 companies we cover.
- Every HDB Score — 1, 5, 10, 20 and 30 years, plus all-time
- Revenue and Net Income Consistency for every period
- Rank all 3,860 companies by any metric, not just three
- Filter by sector and currency, and page through the whole list
- Track your holdings in a portfolio
$99/year $149 founding price
Unlock Holder Dashboard30-day money-back guarantee.
